equity-research

rhc

RHC: Healthcare Giant - Transformation or Stagnation?

Updated 8 Oct 2025

HOLD rating with A$27.36 fair value vs A$31.64 current price. Australian market leader (40%+ share) facing transformation execution risks and European margin pressure.

View note
rfg

RFG: Franchise Operator - Firehouse Gamble with Refinancing Roulette

Updated 8 Oct 2025

ACCUMULATE rating with $22.67 fair value vs $1.52 current price. Multi-brand franchise operator executing strategic transformation with 11% revenue CAGR forecast.

View note
reh

REH: Plumbing Distribution Giant - Premium Price, Leaky Valuation

Updated 8 Oct 2025

Reece trades at $14.93 vs fair value $11.80, offering -21% return potential with 68% loss probability amid construction headwinds and competitive pressures.

View note
rdx

RDX: Chemical Distribution Leader - Recovery Priced In, Execution Required

Updated 8 Oct 2025

HOLD rating with $2.17 fair value vs $2.31 current price. Dominant ANZ position, 5.4% yield, but US expansion struggles and margin recovery challenges limit upside.

View note
qub

QUB: Logistics Giant - Infrastructure Assets Can't Hide the Execution Mess

Updated 8 Oct 2025

HOLD rating with $3.82 fair value vs $4.43 current price. Margin compression and execution risks outweigh defensive infrastructure characteristics.

View note
qbe

QBE: Global Insurance Giant - Transformed but Trapped by Market Euphoria

Updated 8 Oct 2025

QBE Insurance shows strong transformation with 18.2% ROE and 93.1% combined ratio, but fair value analysis suggests 54% overvaluation at current levels.

View note
qan

QAN: Aviation Powerhouse - Flying High on Fleet Renewal Wings

Updated 8 Oct 2025

Dominant Australian airline trading at 38% discount with $19.04 fair value versus $11.89 current price, 20% EBITDA margins, 65% market share.

View note
prn

PRN: Underground Mining Giant - Digging Deep for Value

Updated 8 Oct 2025

Mining services leader trading at 3.1x EV/EBITDA vs 9.0x peer median, fair value $3.92 vs current $2.02, strong execution track record

View note
ppm

PPM: Non-Bank Lending Leader - Royal Commission's Gift That Keeps Giving

Updated 8 Oct 2025

Fair value $3.62 vs current $1.94 (87% upside). Market-leading non-bank lender with 48.8% EBITDA margins, 12.1% ROIC, transforming to capital-light servicing model.

View note
ppe

PPE: Staffing Services Specialist - PALM Scheme Monopoly Meets Olympic Opportunity

Updated 8 Oct 2025

Trading at $0.65 vs $11.26 fair value (1,632% upside). PALM scheme monopoly, Queensland infrastructure catalyst, margins recovering 3.0% to 9.6%. High risk, exceptional reward potential.

View note
pnv

PNV: Medical Device Pioneer - Healing Promise Meets Reality Check

Updated 8 Oct 2025

Medical device manufacturer with 54% revenue growth but trading at 237x EBITDA. Fair value A$1.06 vs current A$1.48 implies 28% downside risk.

View note
ply

PLY: Gaming Developer - All-In on IP, All-Out of Options

Updated 8 Oct 2025

Australia's largest independent game developer attempting high-risk transformation. Fair value $0.089 vs current $0.21. Quality score 3.7/10, 65% IP failure probability.

View note